Confo Therapeutics’ technology stabilizes functional conformations of G protein-coupled receptors to uncover a wide range of previously inaccessible drug targets
Confo Therapeutics, a spin-off of the Vrije Universiteit Brussel and VIB, is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Indigo is developing an implantable sensor that allows to continuously measure glucose and other metabolites for up to two years
Aloxy’s Internet of Things technology is enabling the petrochemical industry to innovate
Sentea leverages silicon photonics to develop a cost-effective fiber optic sensor interrogator
